The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant <named-content content-type="genus-species">Klebsiella pneumoniae</named-content>
ABSTRACT Monoclonal antibodies (MAbs) have the potential to assist in the battle against multidrug-resistant bacteria such as carbapenem-resistant Klebsiella pneumoniae (CR-Kp). However, the characteristics by which these antibodies (Abs) function, such as the role of antibody subclass, must be dete...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
American Society for Microbiology
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8a793b86f7f74f27847385216fbb9426 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8a793b86f7f74f27847385216fbb9426 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8a793b86f7f74f27847385216fbb94262021-11-15T16:19:09ZThe Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant <named-content content-type="genus-species">Klebsiella pneumoniae</named-content>10.1128/mBio.02059-202150-7511https://doaj.org/article/8a793b86f7f74f27847385216fbb94262020-10-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.02059-20https://doaj.org/toc/2150-7511ABSTRACT Monoclonal antibodies (MAbs) have the potential to assist in the battle against multidrug-resistant bacteria such as carbapenem-resistant Klebsiella pneumoniae (CR-Kp). However, the characteristics by which these antibodies (Abs) function, such as the role of antibody subclass, must be determined before such modalities can be carried from the bench to the bedside. We performed a subclass switch on anticapsular monoclonal murine IgG3 (mIgG3) hybridomas and identified and purified a murine IgG1 (mIgG1) hybridoma line through sib selection. We then compared the ability of the mIgG1 and mIgG3 antibodies to control CR-Kp sequence type 258 (ST258) infection both in vitro and in vivo. We found by enzyme-limited immunosorbent assay (ELISA) and flow cytometry that mIgG3 has superior binding to the CR-Kp capsular polysaccharide (CPS) and superior agglutinating ability compared to mIgG1. The mIgG3 also, predictably, had better complement-mediated serum bactericidal activity than the mIgG1 and also promoted neutrophil-mediated killing at concentrations lower than that of the mIgG1. In contrast, the mIgG1 had marginally better activity in improving macrophage-mediated phagocytosis. Comparing their activities in a pulmonary infection model with wild-type as well as neutropenic mice, both antibodies reduced organ burden in a nonlethal challenge, regardless of neutrophil status, with mIgG1 having the highest overall burden reduction in both scenarios. However, at a lethal inoculum, both antibodies showed reduced efficacy in neutropenic mice, with mIgG3 retaining the most activity. These findings suggest the viability of monoclonal Ab adjunctive therapy in neutropenic patients that cannot mount their own immune response, while also providing some insight into the relative contributions of immune mediators in CR-Kp protection. IMPORTANCE Carbapenem-resistant Klebsiella pneumoniae is an urgent public health threat that causes life-threatening infections in immunocompromised hosts. Its resistance to nearly all antibiotics necessitates novel strategies to treat it, including the use of monoclonal antibodies. Monoclonal antibodies are emerging as important adjuncts to traditional pharmaceuticals, and studying how they protect against specific bacteria such as Klebsiella pneumoniae is crucial to their development as effective therapies. Antibody subclass is often overlooked but is a major factor in how an antibody interacts with other mediators of immunity. This paper is the first to examine how the subclass of anticapsular monoclonal antibodies can affect efficacy against CR-Kp. Additionally, this work sheds light on the viability of monoclonal antibody therapy in neutropenic patients, who are most vulnerable to CR-Kp infection.Michael P. MotleyElizabeth Diago-NavarroKasturi BanerjeeSean InzerilloBettina C. FriesAmerican Society for Microbiologyarticleantibody therapymonoclonal antibodiesisotypecarbapenem-resistant Klebsiella pneumoniaeantibiotic resistanceKlebsiellaMicrobiologyQR1-502ENmBio, Vol 11, Iss 5 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
antibody therapy monoclonal antibodies isotype carbapenem-resistant Klebsiella pneumoniae antibiotic resistance Klebsiella Microbiology QR1-502 |
| spellingShingle |
antibody therapy monoclonal antibodies isotype carbapenem-resistant Klebsiella pneumoniae antibiotic resistance Klebsiella Microbiology QR1-502 Michael P. Motley Elizabeth Diago-Navarro Kasturi Banerjee Sean Inzerillo Bettina C. Fries The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant <named-content content-type="genus-species">Klebsiella pneumoniae</named-content> |
| description |
ABSTRACT Monoclonal antibodies (MAbs) have the potential to assist in the battle against multidrug-resistant bacteria such as carbapenem-resistant Klebsiella pneumoniae (CR-Kp). However, the characteristics by which these antibodies (Abs) function, such as the role of antibody subclass, must be determined before such modalities can be carried from the bench to the bedside. We performed a subclass switch on anticapsular monoclonal murine IgG3 (mIgG3) hybridomas and identified and purified a murine IgG1 (mIgG1) hybridoma line through sib selection. We then compared the ability of the mIgG1 and mIgG3 antibodies to control CR-Kp sequence type 258 (ST258) infection both in vitro and in vivo. We found by enzyme-limited immunosorbent assay (ELISA) and flow cytometry that mIgG3 has superior binding to the CR-Kp capsular polysaccharide (CPS) and superior agglutinating ability compared to mIgG1. The mIgG3 also, predictably, had better complement-mediated serum bactericidal activity than the mIgG1 and also promoted neutrophil-mediated killing at concentrations lower than that of the mIgG1. In contrast, the mIgG1 had marginally better activity in improving macrophage-mediated phagocytosis. Comparing their activities in a pulmonary infection model with wild-type as well as neutropenic mice, both antibodies reduced organ burden in a nonlethal challenge, regardless of neutrophil status, with mIgG1 having the highest overall burden reduction in both scenarios. However, at a lethal inoculum, both antibodies showed reduced efficacy in neutropenic mice, with mIgG3 retaining the most activity. These findings suggest the viability of monoclonal Ab adjunctive therapy in neutropenic patients that cannot mount their own immune response, while also providing some insight into the relative contributions of immune mediators in CR-Kp protection. IMPORTANCE Carbapenem-resistant Klebsiella pneumoniae is an urgent public health threat that causes life-threatening infections in immunocompromised hosts. Its resistance to nearly all antibiotics necessitates novel strategies to treat it, including the use of monoclonal antibodies. Monoclonal antibodies are emerging as important adjuncts to traditional pharmaceuticals, and studying how they protect against specific bacteria such as Klebsiella pneumoniae is crucial to their development as effective therapies. Antibody subclass is often overlooked but is a major factor in how an antibody interacts with other mediators of immunity. This paper is the first to examine how the subclass of anticapsular monoclonal antibodies can affect efficacy against CR-Kp. Additionally, this work sheds light on the viability of monoclonal antibody therapy in neutropenic patients, who are most vulnerable to CR-Kp infection. |
| format |
article |
| author |
Michael P. Motley Elizabeth Diago-Navarro Kasturi Banerjee Sean Inzerillo Bettina C. Fries |
| author_facet |
Michael P. Motley Elizabeth Diago-Navarro Kasturi Banerjee Sean Inzerillo Bettina C. Fries |
| author_sort |
Michael P. Motley |
| title |
The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant <named-content content-type="genus-species">Klebsiella pneumoniae</named-content> |
| title_short |
The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant <named-content content-type="genus-species">Klebsiella pneumoniae</named-content> |
| title_full |
The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant <named-content content-type="genus-species">Klebsiella pneumoniae</named-content> |
| title_fullStr |
The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant <named-content content-type="genus-species">Klebsiella pneumoniae</named-content> |
| title_full_unstemmed |
The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant <named-content content-type="genus-species">Klebsiella pneumoniae</named-content> |
| title_sort |
role of igg subclass in antibody-mediated protection against carbapenem-resistant <named-content content-type="genus-species">klebsiella pneumoniae</named-content> |
| publisher |
American Society for Microbiology |
| publishDate |
2020 |
| url |
https://doaj.org/article/8a793b86f7f74f27847385216fbb9426 |
| work_keys_str_mv |
AT michaelpmotley theroleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT elizabethdiagonavarro theroleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT kasturibanerjee theroleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT seaninzerillo theroleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT bettinacfries theroleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT michaelpmotley roleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT elizabethdiagonavarro roleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT kasturibanerjee roleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT seaninzerillo roleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent AT bettinacfries roleofiggsubclassinantibodymediatedprotectionagainstcarbapenemresistantnamedcontentcontenttypegenusspeciesklebsiellapneumoniaenamedcontent |
| _version_ |
1718426914149892096 |